U.S. Regenerative Medicine Market (2024 - 2030) Size, Share & Trends Analysis Report By Product (Cell-based Immunotherapies, Gene Therapies), By Therapeutic Category, And Segment Forecasts

Table of Contents

Chapter 1. Methodology and Scope
                    1.1. Market Segmentation and Scope
                    1.2. Market Definitions
                        1.2.1. Information analysis
                        1.2.2. Market formulation & data visualization
                        1.2.3. Data validation & publishing
                    1.3. Information Procurement
                        1.3.1. Primary Others
                    1.4. Information or Data Analysis
                    1.5. Market Formulation & Validation
                    1.6. Market Model
                    1.7. Objectives
                        1.7.1. Objective 1
                        1.7.2. Objective 2
Chapter 2. Executive Summary
                    2.1. Market Outlook
                    2.2. Segment Snapshot
                    2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
                    3.1. Market Lineage Outlook
                        3.1.1. Parent Market Outlook
                        3.1.2. Related/Ancillary Market Outlook
                    3.2. Market Trends and Outlook
                    3.3. Market Dynamics
                        3.3.1. Presence of a strong pipeline and a large number of clinical trials
                        3.3.2. High economic impact of regenerative medicine
                        3.3.3. Emerging applications of gene therapy in regenerative medicine
                        3.3.4. Increasing government & private funding to support the development of regenerative medicine
                        3.3.5. Technological advancements in regenerative medicine (stem cell, tissue engineering, and nanotechnology)
                        3.3.6. Increase in strategic partnerships to accelerate development & commercialization of regenerative medicines
                        3.3.7. Rising prevalence of chronic diseases & genetic disorders, degenerative diseases, and bone & joint diseases leading to rise in demand for regenerative treatments
                    3.4. Market Restraint Analysis
                        3.4.1. High cost of treatment
                        3.4.2. Regulatory issues pertaining to stem cells, tissues engineering, and regenerative medicines
                    3.5. Business Environment Analysis
                        3.5.1. PESTEL Analysis
                        3.5.2. Porter’s Five Forces Analysis
                        3.5.3. COVID-19 Impact Analysis
Chapter 4. Product Business Analysis
                    4.1. U.S. Regenerative Medicine Market: Product Movement Analysis
                    4.2. Therapeutics
                        4.2.1. Therapeutics Market, 2018 - 2030 (USD Million)
                        4.2.2. Primary Cell-Based Therapeutics
                            4.2.2.1. Primary Cell-Based Therapeutics Market, 2018 - 2030 (USD Million)
                            4.2.2.2. Dermatology
                                4.2.2.2.1. Dermatology Market, 2018 - 2030 (USD Million)
                            4.2.2.3. Musculoskeletal
                                4.2.2.3.1. Musculoskeletal Market, 2018 - 2030 (USD Million)
                            4.2.2.4. Surgical
                                4.2.2.4.1. Surgical Market, 2018 - 2030 (USD Million)
                            4.2.2.5. Dental
                                4.2.2.5.1. Dental Market, 2018 - 2030 (USD Million)
                            4.2.2.6. Others
                                4.2.2.6.1. Others Market, 2018 - 2030 (USD Million)
                        4.2.3. Stem Cell & Progenitor Cell-based therapeutics
                            4.2.3.1. Stem Cell & Progenitor Cell-based therapeutics Market, 2018 - 2030 (USD Million)
                            4.2.3.2. Autologous
                                4.2.3.2.1. Autologous Market, 2018 - 2030 (USD Million)
                            4.2.3.3. Allogenic
                                4.2.3.3.1. Allogenic Market, 2018 - 2030 (USD Million)
                            4.2.3.4. Others
                            4.2.3.5. Others Market, 2018 - 2030 (USD Million)
                        4.2.4. Cell-based Immunotherapies
                            4.2.4.1. Cell-based Immunotherapies Market, 2018 - 2030 (USD Million)
                        4.2.5. Gene Therapies
                            4.2.5.1. Gene Therapies Market, 2018 - 2030 (USD Million)
                    4.3. Tools
                        4.3.1. Tools Market, 2018 - 2030 (USD Million)
                    4.4. Banks
                        4.4.1. Banks Market, 2018 - 2030 (USD Million)
                    4.5. Services
                        4.5.1. Services Market, 2018 - 2030 (USD Million)
Chapter 5. Therapeutic Category Business Analysis
                    5.1. U.S. Regenerative Medicine Market: Therapeutic Category Movement Analysis
                    5.2. Dermatology
                        5.2.1. Dermatology Market, 2018 - 2030 (USD Million)
                    5.3. Musculoskeletal
                        5.3.1. Musculoskeletal Market, 2018 - 2030 (USD Million)
                    5.4. Immunology & Inflammation
                        5.4.1. Immunology & Inflammation Market, 2018 - 2030 (USD Million)
                    5.5. Oncology
                        5.5.1. Oncology Market, 2018 - 2030 (USD Million)
                    5.6. Cardiovascular
                        5.6.1. Cardiovascular Market, 2018 - 2030 (USD Million)
                    5.7. Ophthalmology
                        5.7.1. Ophthalmology Market, 2018 - 2030 (USD Million)
                    5.8. Others
                        5.8.1. Others Market, 2018 - 2030 (USD Million)
Chapter 6. Competitive Landscape
                    6.1. Company Categorization
                    6.2. Strategy Mapping
                    6.3. Company Market/Position Share Analysis, 2022
                    6.4. Company Profiles/Listing
                        6.4.1. AstraZeneca plc.
                            6.4.1.1. Overview
                            6.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                            6.4.1.3. Product Benchmarking
                            6.4.1.4. Strategic Initiatives
                        6.4.2. F. Hoffmann-La Roche Ltd.
                            6.4.2.1. Overview
                            6.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                            6.4.2.3. Product Benchmarking
                            6.4.2.4. Strategic Initiatives
                        6.4.3. Integra Lifesciences Corp.
                            6.4.3.1. Overview
                            6.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                            6.4.3.3. Product Benchmarking
                            6.4.3.4. Strategic Initiatives
                        6.4.4. Astellas Pharma, Inc.
                            6.4.4.1. Overview
                            6.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                            6.4.4.3. Product Benchmarking
                            6.4.4.4. Strategic Initiatives
                        6.4.5. Cook Biotech, Inc.
                            6.4.5.1. Overview
                            6.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                            6.4.5.3. Product Benchmarking
                            6.4.5.4. Strategic Initiatives
                        6.4.6. Bayer AG
                            6.4.6.1. Overview
                            6.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                            6.4.6.3. Product Benchmarking
                            6.4.6.4. Strategic Initiatives
                        6.4.7. Pfizer, Inc.
                            6.4.7.1. Overview
                            6.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                            6.4.7.3. Product Benchmarking
                            6.4.7.4. Strategic Initiatives
                        6.4.8. Merck KGaA
                            6.4.8.1. Overview
                            6.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                            6.4.8.3. Product Benchmarking
                            6.4.8.4. Strategic Initiatives
                        6.4.9. Abbott
                            6.4.9.1. Overview
                            6.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                            6.4.9.3. Product Benchmarking
                            6.4.9.4. Strategic Initiatives
                        6.4.10. Vericel Corp.
                            6.4.10.1. Overview
                            6.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                            6.4.10.3. Product Benchmarking
                            6.4.10.4. Strategic Initiatives
                        6.4.11. Novartis AG
                            6.4.11.1. Overview
                            6.4.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                            6.4.11.3. Product Benchmarking
                            6.4.11.4. Strategic Initiatives
                        6.4.12. GlaxoSmithKline
                            6.4.12.1. Overview
                            6.4.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                            6.4.12.3. Product Benchmarking
                            6.4.12.4. Strategic Initiatives

List of Tables

Table 1 List Of Secondary Sources
Table 2 List Of Abbreviations
Table 3 U.S. Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
Table 4 U.S. Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
Table 5 Participant’s Overview
Table 6 Financial Performance
Table 7 Key Companies Undergoing Expansions
Table 8 Key Companies Undergoing Acquisitions
Table 9 Key Companies Undergoing Collaborations
Table 10 Key Companies Launching New Products/Services
Table 11 Key Companies Undergoing Partnerships
Table 12 Key Companies Undertaking Other Strategies

List of Figures

Fig. 1 Market Others process
Fig. 2 Data triangulation techniques
Fig. 3 Primary Others pattern
Fig. 4 Market Others approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Market summary, 2023 (USD Million)
Fig. 9 Market segmentation & scope
Fig. 10 Market driver impact
Fig. 11 Market restraint impact
Fig. 12 Penetration & growth prospect mapping
Fig. 13 Porter’s analysis
Fig. 14 SWOT analysis
Fig. 15. U.S. regenerative medicine therapeutics market, 2018 - 2030 (USD Million)
Fig. 16 U.S. primary cell-bases therapeutics market, 2018 - 2030 (USD Million)
Fig. 17 U.S. dermatology primary cell-bases therapeutics market, 2018 - 2030 (USD Million)
Fig. 18 U.S. musculoskeletal primary cell-bases therapeutics market, 2018 - 2030 (USD Million)
Fig. 19 U.S. surgical primary cell-bases therapeutics market, 2018 - 2030 (USD Million)
Fig. 20 U.S. dental primary cell-bases therapeutics market, 2018 - 2030 (USD Million)
Fig. 21 U.S. other primary cell-based therapeutics market, 2018 - 2030 (USD Million)
Fig. 22 U.S. autologous stem cell & progenitor cell-based therapeutics market, 2018 - 2030 (USD Million)
Fig. 23 U.S. autologous stem cell & progenitor cell-based therapeutics market, 2018 - 2030 (USD Million)
Fig. 24 U.S. allogeneic stem cell & progenitor cell-based therapeutics market, 2018 - 2030 (USD Million)
Fig. 25 U.S. other stem cell & progenitor cell-based therapeutics market, 2018 - 2030 (USD Million)
Fig. 26 U.S. cell-based immunotherapies market, 2018 - 2030 (USD Million)
Fig. 27 U.S. gene therapies market, 2018 - 2030 (USD Million)
Fig. 28 U.S. regenerative medicines tools, 2018 - 2030 (USD Million)
Fig. 29 U.S. banks market for regenerative medicine, 2018 - 2030 (USD Million)
Fig. 30 U.S. regenerative medicine services market, 2018 - 2030 (USD Million)
Fig. 31 Regenerative medicine market: Therapeutic category outlook and key takeaways
Fig. 32 Regenerative medicine market: Therapeutic category movement analysis (USD Million)
Fig. 33 U.S. dermatological therapeutics category market, 2018 - 2030 (USD Million)
Fig. 34 U.S. musculoskeletal therapeutics category market, 2018 - 2030 (USD Million)
Fig. 35 U.S. immunology & inflammation therapeutics category market, 2018 - 2030 (USD Million)
Fig. 36 U.S. oncology therapeutics category market, 2018 - 2030 (USD Million)
Fig. 37 U.S. cardiovascular therapeutics category market, 2018 - 2030 (USD Million)
Fig. 38 U.S. ophthalmology therapeutics market, 2018 - 2030 (USD Million)
Fig. 39 U.S. other therapeutics category market, 2018 - 2030 (USD Million)
Fig. 40 Market participant categorization
Fig. 41 Regenerative Medicine Market share analysis, 2023
Fig. 42 Strategy framework